Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.79 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.79 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.79 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | RXRA | P19793 | 1/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.70 |
| ▸ | CDK2 | P24941 | 1/20 | 0.70 |
| ▸ | RXRB | P28702 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pomiferin A SCHEMBL30087017 | 1.00 | KARS1 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR | |
| Pomiferin A SCHEMBL4549111 | 1.00 | KARS1 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR | |
| Pomiferin A SCHEMBL1210740 | 1.00 | KARS1 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR | |
| Pomiferin A SCHEMBL13039025 | 1.00 | KARS1 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR | |
| Pomiferin A SCHEMBL2546195 | 1.00 | KARS1 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL20866442 | 0.91 | KARS1 (0.83) | KARS1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL16298228 | 0.89 | CYP3A4 (0.80) | KARS1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL4943352 | 0.88 | CYP3A4 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL27863 | 0.88 | CYP3A4 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR | |
| SCHEMBL17158674 | 0.88 | CYP3A4 (1.00) | KARS1CYP3A4MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822692-B2 | Diterpenoid derivatives endowed of biological properties | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE, S.P.A. (IT) | 2014-09-02 | — | — | US | disclosed |
| EP-2632892-B1 | DITERPENOID DERIVATIVES ENDOWED OF BIOLOGICAL PROPERTIES | SIGMA TAU IND FARMACEUTI (IT) | 2014-07-30 | — | — | EP | disclosed |
| US-20130310423-A1 | DITERPENOID DERIVATIVES ENDOWED OF BIOLOGICAL PROPERTIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-11-21 | — | — | US | disclosed |
| EP-2632892-A1 | DITERPENOID DERIVATIVES ENDOWED OF BIOLOGICAL PROPERTIES | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055894-A1 | DITERPENOID DERIVATIVES ENDOWED OF BIOLOGICAL PROPERTIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310423-A1 | DITERPENOID DERIVATIVES ENDOWED OF BIOLOGICAL PROPERTIES | PTGIS, CYP11B2, CYP11B1 | KARS1 4322/4885CYP3A4 1340/4885MEN1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.